Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 18 Apr 2023 16:46 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma – Minutes of Ordinary General Meeting | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 11 Apr 2023 10:17 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Notice of Annual General Meeting on 18 April 2023 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 30 Mar 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Annual Report for 2022 | 20103010 Biotechnology | Årsrapporter og revisjonsberetninger |
| 16 Feb 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presents fourth quarter and second half 2022 results | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 09 Feb 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 15 Dec 2022 15:08 CET |
LYTIX BIOPHARMA AS | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 15 Dec 2022 15:08 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Dec 2022 19:15 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: GRANT OF SHARE OPTIONS | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 17 Nov 2022 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma third quarter 2022 results | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 14 Nov 2022 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma announces expansion of the ATLAS-IT-05 study to Europe | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 10 Nov 2022 14:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presents compelling data in collaboration with research groups at National Cancer Institute and Weill Cornell Medicine, USA. | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 10 Nov 2022 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of third quarter 2022 results, Thursday 17 November | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 01 Nov 2022 15:25 CET |
LYTIX BIOPHARMA AS | Invitation to Capital Markets Day in Oslo, November 22, 2022 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 20 Oct 2022 13:54 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to host Capital Markets Day - November 22, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
| 05 Oct 2022 14:52 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces that an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 29 Sep 2022 11:23 CEST |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Sep 2022 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces approval to expand the ATLAS-IT-05 study to Europe | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 05 Sep 2022 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma appoints Stephen Worsley as Chief Business Officer | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 01 Sep 2022 18:41 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Mandatory notification of trade | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 27 Aug 2022 12:48 CEST |
LYTIX BIOPHARMA AS | Mandatory notification of trade | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 26 Aug 2022 15:06 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Mandatory notification of trade | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 25 Aug 2022 07:59 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Second quarter and first half of 2022 results | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 18 Aug 2022 09:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of first half and second quarter 2022 results, Thursday August 25th, 2022 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 05 Jun 2022 15:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS announces that LTX-315 in combination with Adoptive Cell Therapy has been shown to generate tumor-specific T cells and stabilize the disease in patients with progressive metastatic soft tissue sarcoma (STS) | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 27 May 2022 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS announces that an abstract on LTX-315 in combination with Adoptive Cell Therapy is selected for a poster presentation at ASCO 2022 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 19 May 2022 16:41 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma – Invitation to Capital Markets Day in Oslo, June 1, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
| 12 May 2022 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma presents first quarter 2022 results | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 05 May 2022 09:56 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of first quarter 2022 results, Thursday 12 May | 20103010 Biotechnology | Non-regulatory press releases |
| 03 May 2022 13:07 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to host Capital Markets Day, save the date - June 1, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
| 28 Apr 2022 11:54 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to present at the American Society of Clinical Oncology (ASCO) Annual Meeting | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 22 Apr 2022 14:13 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma – Minutes of Ordinary General Meeting | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 20 Apr 2022 13:08 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma - Share capital increase from exercise of warrants | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Apr 2022 09:10 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Annual Report for 2021 | 20103010 Biotechnology | Årsrapporter og revisjonsberetninger |
| 05 Apr 2022 13:57 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma receives milestone payment from Verrica Pharmaceuticals Inc. triggered by first patient dosed with LTX-315 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 15 Mar 2022 06:36 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma - Exercise of warrants | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 11 Mar 2022 08:13 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma to present at the 6th Annual Next Gen Immuno-Oncology Congress, UK | 20103010 Biotechnology | Non-regulatory press releases |
| 17 Feb 2022 07:06 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma fourth quarter 2021 results | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 15 Feb 2022 17:27 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma granted 3 MNOK from Oslo Regional Research Fund | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 10 Feb 2022 09:22 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of fourth quarter 2021 results, Thursday 17 February | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 10 Feb 2022 09:12 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of fourth quarter 2021 results, Thursday 17 February | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 17 Dec 2021 10:35 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 17 Dec 2021 10:35 CET |
LYTIX BIOPHARMA AS | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 08 Dec 2021 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS Announces that First Patient Started Treatment in the ATLAS-IT-05 clinical trial | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 25 Nov 2021 07:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma third quarter 2021 results | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 22 Nov 2021 07:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of third quarter 2021 results, Thursday 25 November | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 18 Nov 2021 15:35 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS Announces FDA Acceptance of Verrica Pharmaceuticals' IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 12 Nov 2021 08:00 CET |
LYTIX BIOPHARMA AS | Lytix presents encouraging preclinical data in triple negative breast cancer in collaboration with Weill Cornell Medicine | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 22 Oct 2021 09:45 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma granted European Patent for LTX-315 in combination with chemotherapeutic agent | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 20 Oct 2021 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS to Present at Investordagene 2021 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 22 Sep 2021 18:20 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma strengthens patent protection of lead candidate LTX-315 in the US | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |